



Dear Dr,

On behalf of the Workshop & Study Committee of the European Neuroendocrine Association, it is with great pleasure to invite you to participate as a member of ENEA in the International 'RESISTANT PROLACTINOMA STUDY' launched by the ENEA Workshop and Study Committee during the 5th ENEA Workshop: Hyperprolactinemia and other endocrine causes of infertility that took place in Saint Petersburg, Russia, in 2017.

The purpose of the study is to investigate the clinical and biochemical features, morphological characteristics, diagnostic approaches, treatment regimens and options as well as outcomes of DA-resistant prolactinomas that we have defined as the prolactinomas treated for at least 6 months with at least 3 mg/week cabergoline without achieving prolactin levels normalization.

The large scientific community of ENEA involved in therapy of pituitary diseases is able to collect enough data on clinical features and cure of this rather rare subset of prolactinomas, which will help to identify the best treatment strategies for these patients.

A target number of 600 patients has been planned to be recruited to achieve a sound conclusion. The top contributors will be recognized as co-authors of scientific papers, whereas the contributors providing less patients will be recognized as members of the RESISTANT PROLACTINOMA STUDY Consortium, a new collaborative group of clinicians and scientists studying resistant prolactinomas.

For your information: The Study will use the platform Synergy2go hosted on the ARUBA SERVER (Society: ARUBA spa). All data will be protected in compliance with the European GDPR (privacy law currently in force).

We do hope you will be able to contribute to this study. Please do not hesitate to contact us for any clarification or assistance.

We are looking forward to hearing from you **by the end of June**.

Sincerely,